Dernières nouvelles pour Tempus AI (NASDAQ:TEM) Stock

TEMPUS AI INC

Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

News

Contracts

Diana Shipping Enters Time Charter Contract For m/v Astarte With Gross Charter Rate $12,500 Minus 5% Commission Paid To Third Parties For Period Until Minimum Aug. 16, 2026 Up To Maximum Oct. 16, 2026

Barclays analyst Ramsey El-Assal maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Overweight and lowers the price target from $230 to $175.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Fiserv, Lowers Price Target to $175

<a href="https://www.youtube.com/watch?v=O1jOi7Wce8I" title="https://www.youtube.com/watch?v=O1jOi7Wce8I">https://www.youtube.com/watch?v=O1jOi7Wce8I</a>

Macro Economic Events

Politics

Global

Economics

General

President Trump On Russia, Says We're Going To Do Secondary Sanctions Unless We Make A Deal; We Might Make A Deal, You Don't Know; Will Confirm New Russia Deadline Tonight Or Tomorrow

WIIM

STXS

Stereotaxis shares are trading higher after the company announced it received FDA 510(k) clearance for its MAGic sweep catheter.

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) with a Market Perform and raises the price target from $70 to $71.

CUBI

Keefe, Bruyette & Woods Maintains Market Perform on Customers Bancorp, Raises Price Target to $71

<a href="https://www.youtube.com/watch?v=O1jOi7Wce8I">https://www.youtube.com/watch?v=O1jOi7Wce8I</a>
&nbsp;

President Trump Says We'll Be Announcing Pharma Tariffs In The Very Near Future; We Will Be Dealing With UK On Pharma; We Wouldn't Use Pharma Tariffs As A Block For UK

Ostin Technology shares are trading lower. The company announced a 1-for-25 reverse stock split.

CLDI

Calidi Biotherapeutics shares are trading lower after the company announced a 1-for-12 reverse stock split.

<a href="https://www.youtube.com/watch?v=hfjhPO-SUWo">https://www.youtube.com/watch?v=hfjhPO-SUWo</a>
&nbsp;

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

President Trump On Gaza, Says We Hope The Food Goes To The People Who Need It; It's Difficult To Deal With Hamas; I'm Speaking To Netanyahu And We're Coming Up With Various Plans; We're Going To Set Up Food Centers; Food Centre Will Be Walk-In, With No Boundaries

ENTX

Entera Bio shares are trading higher after the company announced it received an FDA agreement to support its EB6143 BMD NDA filing.

Management

KITT

Nauticus Robotics Appoints Jimena Begaries As Interim CFO, Effective July 25, 2025; Succeeds Victoria Hays

President Trump Speaking On Russia, Says I'm Going To Make A New Deadline For About 10 Or 12 Days From Today; We Just Don't See Any Progress Being Made

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) with a Market Perform and raises the price target from $38 to $42.

Keefe, Bruyette & Woods Maintains Market Perform on BankUnited, Raises Price Target to $42

<ul>
<li>UNH</li>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>HOOD</li>
<li>BULL</li>
<li>GOOGL</li>
<li>AMD</li>
<li>MSFT</li>
<li>RKT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

BULL

GOOGL

HOOD

MSFT

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 28, 2025 (Via Swaggy Stocks)

Barclays analyst Kannan Venkateshwar maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Underweight and lowers the price target from $341 to $275.

CHTR

Barclays Maintains Underweight on Charter Communications, Lowers Price Target to $275

Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) will release earnings results for the second quarter, after the closing <a href="https://www.benzinga.com/quote/nue/earnings">bell on Monday, July 28.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $2.70 per share, up from $2.68 per share in the year-ago period. Nucor projects to report quarterly revenue at $8.48 billion, compared to $8.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 18, the steelmaker said that it expects earnings to come in between $2.55 and $2.65 per share for the quarter ending July 5.
Nucor shares gained 3.1% to close at $145.83 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/nue/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Morgan Stanley analyst Carlos De Alba maintained an Overweight rating and raised the price target from $134 to $149 on June 20, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Curt Woodworth maintained a Buy rating and cut the price target from $153 to $147 on May 29, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Jefferies analyst Christopher LeFemina maintained a Hold rating and boosted the price target from $125 to $135 on Jan. 29, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Citigroup analyst Alexander Hacking maintained a Buy rating and cut the price target from $240 to $160 on Dec. 19, 2024. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying NUE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/NUE/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28032345/image-414-1024x574.png" alt="" class="wp-image-1002745" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28032345/image-414-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28032345/image-414-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28032345/image-414-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28032345/image-414.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

Earnings

Long Ideas

Markets

Nucor Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Burke &amp; Herbert Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHRB#NASDAQ">BHRB</a>) with a Outperform and raises the price target from $70 to $72.

BHRB

Keefe, Bruyette & Woods Maintains Outperform on Burke & Herbert Financial, Raises Price Target to $72

As of July 28, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Uniti Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>)</h3>
<ul class="wp-block-list">
<li>Uniti Group will report its second quarter financial results prior to the opening of trading on the Nasdaq Stock Exchange on Aug. 5. The company's stock jumped around 34% over the past month and has a 52-week high of $6.31.</li>
<li>RSI Value: 81.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>UNIT Price Action: Shares of Uniti gained 0.4% to close at $5.80 on Friday.</li>
<li>Edge Stock Ratings: 83.99 Momentum score with Value at 41.44.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/unit"><img loading="lazy" decoding="async" width="411" height="196" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28042345/image-420.png" alt="" class="wp-image-1002828" style="width:321px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28042345/image-420.png 411w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28042345/image-420-300x143.png 300w" sizes="(max-width: 411px) 100vw, 411px" /></a></figure>
<h3 class="wp-block-heading">Zillow Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>)</h3>
<ul class="wp-block-list">
<li>On July 18, DA Davidson analyst Tom White maintained Zillow with a Buy and maintained a price target of $85. The company's stock gained around 14% over the past month <a href="https://www.benzinga.com/quote/ZG">has a 52-week high</a> of $86.58.</li>
<li>RSI Value: 73.4</li>
<li>ZG Price Action: Shares of Zillow jumped 1.1% to close at $78.16 on Friday.</li>
</ul>
Don't miss out on the full BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">compare all the key stocks now</a>.
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

JOBY

UNIT

Top 2 Real Estate Stocks That May Collapse This quarter

Roadzen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) ("Roadzen" or the "Company"), a global leader in AI at the convergence of insurance and mobility, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,730,769 ordinary shares at an offering price of $1.30 per share, in a registered direct offering (the "Offering").
The gross proceeds to the Company from the Offering are estimated to be approximately $2.25 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about July 29, 2025, subject to the satisfaction of customary closing conditions.
Maxim Group LLC is acting as the sole placement agent in connection with the Offering.

Offerings

RDZN

Roadzen Announces $2.25M Registered Direct Offering Of 1,730,769 Shares At $1.30 Per Share

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics shares are trading lower after the company announced topline data from its ATH434-202 open-label Phase 2 clinical trial.

Short Sellers

Press Releases

TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Tempus to Report Second Quarter 2025 Financial Results on August 8

Opinion

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM

Tempus AI, Inc. (TEM) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

TEM Class Action Reminder: Robbins LLP Reminds Tempus AI, Inc. Investors of the Class Action Lawsuit - Contact us for more information

TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM

Legal

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. (NASDAQ: TEM)

AVAI

BLCO

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Tempus AI

Actualités

Dernières nouvelles pour Tempus AI (NASDAQ:TEM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL